TY  - JOUR
TI  - Evaluation of survival and treatment correlation with
ERCC-1 expression/amplification in Non-small cell
carcinoma
AB  - Aim: The excision repair cross-complementation group 1 (ERCC-1) protein is a potential prognostic biomarker of the efficacy of
platinum-based chemotherapy in non–small-cell lung cancer (NSCLC). The purpose of this study was to evaluate the clinicopathology
and prognostic significance of ERCC-1 expression, ERCC-1 (19q13) amplification in NSCLC patients; and the relationship between
platinum-based chemotherapy.
Materials and Methods: We used the ERCC-1 antibody to measure the level of expression of ERCC-1 protein by immunohistochemical
analysis from 351 patients and ERCC-1 gene copy number was evaluated by fluorescence in situ hybridization (FISH) in tumors
from 81 patients.
Results: ERCC-1 expression in tumor cells was positive in 312 patients (88.9%). The ERCC-1 amplification in tumor cells was positive
in 58 patients (71.6%) out of 81. The ERCC-1 amplification was also more frequent in early-stage tumors than late-stage tumors
(p = 0.025). In the patients with positive ERCC-1 expression, longer overall survival was associated with early stage NSCLC (p =
0.001). Patients having adenocarcinoma with negative ERCC-1 expression demonstrated longer overall survival than patients with
squamous cell carcinoma (p = 0.037).
Conclusion: Our study demonstrated that increased ERCC-1 amplification is not associated with ERCC-1 protein expression. High
ERCC-1 expression in patients with early-stage NSCLC is a good prognostic factor, although it is a negative predictor, indicating
treatment resistance, in patients with advanced-stage NSCLC receiving platinum-based chemotherapy. We suggest that patients
having adenocarcinoma with negative ERCC-1 expression benefit more with platinum-based chemotherapies.
AU  - baser oncel, sevin
AU  - ARMAN KARAKAYA, YELİZ
AU  - Gokoz Dogu, Gamze
AU  - Bir, Ferda
AU  - Gormez, Aysegul
DO  - 10.5455/annalsmedres.2021.03.220
PY  - 2021
JO  - Annals of Medical Research
VL  - 28
IS  - 12
SN  - 2636-7688
SP  - 2160
EP  - 2167
DB  - TRDizin
UR  - http://search/yayin/detay/514596
ER  -